News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Telomir Pharmaceuticals announces potentially groundbreaking findings from preclinical progeria lifespan study demonstrating restoration of shortened lifespan and normalization of accelerated aging with Telomir-1 -
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Telomir Pharmaceuticals announces promising findings from copper binding studies with Telomir-1, addressing Wilson's disease and metal toxicity. Telomir-1 shows potential in preclinical models for multiple conditions -
-
PRESS RELEASE
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Telomir Pharmaceuticals, Inc. raises $1 million in equity funding through The Starwood Trust, reinforcing financial strength. Telomir-1 shows transformative potential in addressing age-related conditions -
-
PRESS RELEASE
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results showcasing Telomir-1's efficacy in reversing key parameters of Type 2 diabetes mellitus, potentially addressing insulin resistance at its root -
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results confirming the efficacy of Telomir-1 in age-reversal science. The study demonstrates significant age-reversal effects in model organisms, supporting longevity and improved healthspan
